Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | PDCD1 | Q15116 | 15/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 15/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13256989 | 0.83 | CNR2 (0.51) | CNR1CNR2SMN1; SMN2 | |
| SCHEMBL3790780 | 0.83 | CNR2 (0.51) | CNR1CNR2SMN1; SMN2 | |
| SCHEMBL16238661 | 0.79 | CNR1 (0.46) | CNR1CNR2PDCD1CD274SMN1; SMN2 | |
| SCHEMBL16238780 | 0.78 | ALDH1A1 (0.49) | CNR1CNR2PDCD1CD274SMN1; SMN2 | |
| SCHEMBL16238430 | 0.78 | PDCD1 (0.38) | PDCD1CD274SMN1; SMN2RAB9A | |
| SCHEMBL16238765 | 0.78 | CNR2 (0.43) | CNR1CNR2PDCD1CD274SMN1; SMN2 | |
| SCHEMBL16238760 | 0.77 | CNR1 (0.49) | CNR1CNR2PDCD1CD274SMN1; SMN2 | |
| SCHEMBL3710751 | 0.74 | HSD11B1 (0.53) | CNR1CNR2SMN1; SMN2 | |
| SCHEMBL3710748 | 0.74 | HSD11B1 (0.53) | CNR1CNR2SMN1; SMN2 | |
| SCHEMBL3713502 | 0.73 | HSD11B1 (0.52) | CNR1CNR2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889670-B2 | Heterocyclic compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-18 | — | — | US | claimed |
| US-20110312944-A1 | Heterocyclic Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312944-A1 | Heterocyclic Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CNR1 2/4885CNR2 1/4885PDCD1 3527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.